Patient Characteristics
| Patient | Primary tumor type | mAb first/second administration | H-score of membrane staining | Best response* |
| 1 | Breast cancer | 8 mg/24 mg | 35 | PD |
| 2 | Head and neck cancer | 24 mg/1 mg/kg | 80 | ND |
| 3 | Cervical cancer | 8 mg/30 mg/kg | 184 | PD |
| 4 | Ovarian cancer | 8 mg/30 mg/kg | 195 | PD |
| 5 | Prostate cancer | 8 mg/0.5 mg/kg | 200 | SD |
| 6 | Colorectal cancer | 8 mg/—† | 18 | ND |
↵* First response evaluation was performed at 12 wk after treatment initiation to allow sufficient time for beneficial treatment effect that could be detected by RECIST 1.1.
↵† Patient 6 was discovered to have brain metastasis as seen in baseline immuno-PET study and therefore was removed from further studies.
SD = stable disease; PD = progressive disease according to RECIST 1.1; ND = not determined.